CN102091055A - Calcium dobesilate capsule and preparation method thereof - Google Patents
Calcium dobesilate capsule and preparation method thereof Download PDFInfo
- Publication number
- CN102091055A CN102091055A CN 201110030889 CN201110030889A CN102091055A CN 102091055 A CN102091055 A CN 102091055A CN 201110030889 CN201110030889 CN 201110030889 CN 201110030889 A CN201110030889 A CN 201110030889A CN 102091055 A CN102091055 A CN 102091055A
- Authority
- CN
- China
- Prior art keywords
- recipe quantity
- carboxymethyl cellulose
- calcium dobesilate
- calcium
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a calcium dobesilate capsule and a preparation method thereof. The calcium dobesilate capsule is prepared from calcium dobesilate, croscarmellose sodium, magnesium stearate and polyvinyl pyrrolidone, wherein every 1000 calcium dobesilate capsules contain 500g of calcium dobesilate, 20-50g of croscarmellose sodium and 2-6g of magnesium stearate. In addition, a traditional preparation method is improved in the invention, and the improved method comprises the following steps: on the basis of taking the croscarmellose sodium as a disintegrating agent and taking the magnesium stearate as a lubricating agent, adding a proper amount of the polyvinyl pyrrolidone to prepare a bonding agent; preparing the bonding agent and the calcium dobesilate as well as the croscarmellose sodium into granules by a multi-step granulation method; and spraying the ethanol solution of the magnesium stearate onto the surfaces of the granules to obtain calcium dobesilate capsules with stable quality, high dissolution rate and small content uniformity.
Description
Technical field
The present invention relates to a kind of field of pharmaceutical preparations, more particularly the invention provides a kind of calcium hydrophenyl sulfonate capsule and preparation method thereof.
Background technology
Calcium hydrophenyl sulfonate capsule, English name: Calcium Dobesilate Capsules.This product Main Ingredients and Appearance is a calcium dobesilate, and its chemical name is: 2, and 5-dihydroxy benzenes sulfonic acid calcium monohydrate.Its structural formula is:
Molecular formula: C
12H
10CaO
10S
2H
2O, molecular weight: 436.42.
Improving constantly along with living standard in recent years.The diabetics that is called as affluenza has the trend that increases year by year.The many complication that cause by diabetes.Become one of big factors of harm people ' s health.Diabetic renal papillary necrosis (DR) is one of severe complication of diabetes.In European and American countries four big diseases causing blindnesses, occupy first.The incidence rate of China's diabetics retinopathy is about 45-58% according to statistics.According to the interrelated data statistics, diabetic duration is 35-39% in its DR incidence rate of person below 5 years; Course of disease 5-10 person is 50-56.7%.Increase to more than 10 years and be 69-90%.Be associated with hypertension, hyperlipidemia, hemorheology as the while whole body and learn obvious changer is arranged, then the DR incidence rate is higher.20 years type ii diabetes persons of the course of disease, oral antidiabetic drug, its DR incidence rate is 60%, injection islets of langerhans rope person is 84%.As seen existing antidiabetic drug can not reduce generation and the development of DR.
Studies confirm that at present the key that DR takes place is the retinal tissue anoxia.Early stage pathological change is the pericapillary cells forfeiture, and microangioma forms, and capillary basement membrane thickens, and blood-retina barrier destroys, hemorrhage, oozing of blood and retinal edema.Late period, visible new vessels, abnormal vascular formed and fibroplasia, finally caused vitreous hemorrhage, even detachment of retina.At present the Study on Pathogenesis of DR is focused mostly at aspects such as the accumulation of unusual, the protein non-enzyme glycosylation product of polyhydric alcohol metabolic pathway, protein kinase C activation, oxidative stress theory, effect of cytokines.Tight clinically glycemic control and laser therapy can reduce patient's the blindness and blinding, but can not reverse the retina injury that has existed.And aldose reductase inhibitor and inhibitors of protein kinase C treatment targetedly can not be played better curative effect.Calcium dobesilate is the treatment that is used for DR the earliest, also is to treat the comparatively ideal medicine of DR at present.
At present the preparation at the calcium dobesilate of China's list marketing has conventional tablet, dispersible tablet, granule and capsule, and wherein capsule is most widely used clinically general, and two kinds of specifications of 0.5g and 0.25g are arranged.
As disclosing the preparation method of following a kind of calcium hydrophenyl sulfonate capsule in the prior art:
One, prescription
The material name consumption
Calcium dobesilate-hydrate 521.5g
(being equivalent to calcium dobesilate 500g)
Carboxymethyl starch sodium 45.0g
Magnesium stearate 5.0g
Make 1000
Two, preparation technology
1, the supplementary material pulverize separately is crossed 100 mesh sieves, following dry 4 hours respectively at 60 ℃;
2, take by weighing calcium dobesilate-hydrate, carboxymethylstach sodium and the magnesium stearate of recipe quantity, evenly mixed by the equivalent incremental method;
3, get above-mentioned mixed powder art, measure content, the moisture (control moisture scope 4%-6%) of intermediate, qualified back fill gets final product in No. 0 capsule.
But there are some problems in this technology:
1, adopt direct blended granule, mobile relevant with the character of raw material itself, loading amount instability, the phenomenon that content uniformity is big take place because of the mobile difference of raw material itself in regular meeting in the time of in stowing operation.And cause the adhesions such as jumper bar, calculating dial of capsule filler easily, cause producing and normally to carry out.
2, magnesium stearate is a lubricant in this prescription, when total mixing, to reach to mix 50 and change (15 minutes) fully mix homogeneously, but under these process conditions the non-compliant regulation of dissolution of product.Be lower than this operation requirement as incorporation time, it is inhomogeneous to cause material to mix, and granule content there are differences, and sticking etc. can take place in stowing operation cause content uniformity.
Because the problems referred to above, this process scale type often causes certain difficulty when producing, thereby has limited application.The patent application of application number 200510110019.2 has proposed a kind of new hydroxyl sulfoacid calcium capsule and preparation technology.Per 1000 capsules are grouped into by the one-tenth of following weight: calcium dobesilate 500g, carboxymethyl starch sodium 20～40g, Rikemal B 200 2.5～5g, 95% ethanol 30g.Its preparation technology is: 1. the supplementary material pulverize separately is crossed 100 mesh sieves; 2. the calcium dobesilate monohydrate is dropped into the high speed wet granulator and open stirring at low speed 1min, 120 rev/mins, add 95% alcohol granulation, stirring at low speed 3min, 120 rev/mins; 3. 60～65 ℃ of aeration-dryings, 16 mesh sieve granulate; 4. add carboxymethyl starch sodium, Rikemal B 200, mix 50 and changeed sampling and measuring intermediate content and moisture 15 minutes; 5. according to intermediate assay result, contain calcium dobesilate 0.5g by every capsules and calculate the capsule loading amount.Though defectives such as the disintegration time, the dissolution that cause medicine because of incorporation time is long that above-mentioned preparation method has avoided the employing magnesium stearate to cause to a certain extent are defective.But the capsule stability of its preparation and disintegrating property also have very big room for improvement.
In view of this, special proposition the present invention.
Summary of the invention
The invention provides calcium hydrophenyl sulfonate capsule that a kind of advantages of simple of writing out a prescription, feasible process are stable, controllable product quality is good and preparation method thereof.
First purpose of the present invention is to provide a kind of calcium hydrophenyl sulfonate capsule.Calcium hydrophenyl sulfonate capsule related substance provided by the present invention is low, good stability, and dissolution is good, and is quality controllable.Second purpose of the present invention is to provide the preparation method of above-mentioned calcium hydrophenyl sulfonate capsule.For achieving the above object, the present invention adopts following technical scheme:
A kind of calcium hydrophenyl sulfonate capsule, described capsule is prepared from by calcium dobesilate, cross-linking sodium carboxymethyl cellulose, magnesium stearate and polyvinylpyrrolidone, wherein per 1000 calcium hydrophenyl sulfonate capsules contain: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 20～50g, magnesium stearate 2～6g.
Per 1000 of described calcium hydrophenyl sulfonate capsule contains: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 30～40g, magnesium stearate 3～5g.
Per 1000 of described calcium hydrophenyl sulfonate capsule contains: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 35g, magnesium stearate 4g, polyvinylpyrrolidone 3g.
A kind of preparation method of calcium hydrophenyl sulfonate capsule as mentioned above, described preparation method comprise the particulate preparation of calcium dobesilate, and described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent, mix, the system primary granule to the cross-linked carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35-65% and recipe quantity 30-70%;
(4) with adding 5/13 binding agent and the calcium dobesilate of recipe quantity 35-65%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-70% in the primary granule that makes, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying, fill.
The drying of described step 5 is carried out drying for the calcium dobesilate raw material powder of will granulate back gained granule and recipe quantity 0-35%, the cross-linked carboxymethyl cellulose raw material powder mixing of recipe quantity 0-40%.
Described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 45-60% and recipe quantity 40-70%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 40-55%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-60%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying, fill;
Preferred described particulate preparation method is:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 55% and recipe quantity 60%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying, fill;
Described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35-50% and recipe quantity 40-50%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 30-45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously carries out drying, fill with gained granule and the calcium dobesilate raw material powder of 5-35%, the cross-linked carboxymethyl cellulose raw material powder of 10-30% after the spraying;
Preferred described particulate preparation method is:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 40% and recipe quantity 40%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 25% calcium dobesilate raw material powder, 25% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, fill.
Pretreatment is in the described step 1: calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ± 5 ℃ of dryings 1 hour.
Alcoholic solution in the described step 5 is 40-80ml, preferred 60ml; Concentration of alcohol is 75-95%, preferred 85%.
Drying in the described step 5 is in fluid bed 55-85 ℃, dry 0.5-1.5 hour; Preferably with 70 ℃, dry 0.5-1.5 hour, be filled in the 0# Capsules after calculating loading amount according to the intermediate testing result, the present invention is carried out further introducing in detail below 800～1000/minute of the capsule filling speeds.
Calcium dobesilate is a kind of blood capillary circulation improving agent, clinically is usually used in the multiple prevention and treatment of diseases that diabetic retinopathy, varicosis syndrome etc. are caused by blood capillary circulatory disturbance.It is white or off-white color hygroscopic powder, powder fluidity is poor, therefore, when calcium hydrophenyl sulfonate capsule is write out a prescription design, to fully take into account the mobile poor lubricant that therefore need add of calcium dobesilate itself on the one hand and improve its flowability, will consider also that on the other hand adding lubricant still will keep the qualified dissolution of medicine afterwards.
The present invention has continued to use magnesium stearate in the calcium hydrophenyl sulfonate capsule tradition prescription as lubricant, and magnesium stearate is good lubricant, and it is used widely in the preparation process of medicine, and effect has also obtained abundant checking.In the prior art calcium hydrophenyl sulfonate capsule mostly adopt with after the supplementary material drying directly with the powder filled capsules, since magnesium stearate with need regular hour and the rotating speed could abundant mixing mixing of calcium dobesilate and Carboxymethyl cellulose sodium, and often be easy under this condition cause capsular dissolution defective.Therefore, the two is difficult to take into account.
The invention provides a kind of preparation method of new calcium hydrophenyl sulfonate capsule, as disintegrating agent, magnesium stearate is as lubricant with crosslinked Carboxymethyl cellulose sodium for this calcium hydrophenyl sulfonate capsule.In order to overcome in the prior art supplementary material powder is directly mixed problems such as the content uniformity that may occur in the encapsulated process and dissolution be defective, the present invention improves the traditional preparation process method, be specially with crosslinked Carboxymethyl cellulose sodium as disintegrating agent, on the basis of magnesium stearate as lubricant, add an amount of polyvinylpyrrolidone and prepare binding agent, by the multistep granulation with binding agent with calcium dobesilate and exchange Carboxymethyl cellulose sodium and be prepared into granule, alcoholic solution with magnesium stearate is sprayed to particle surface again, on the one hand, can be on granule with the magnesium stearate even spraying, play good lubrication, on the other hand, with the alcoholic solution of magnesium stearate granule is wrapped up also can play and eliminate electrostatic effect, help follow-up mixing, thereby further reach the purpose that reduces content uniformity.Granule after the spraying is carried out dried, and intermediate is detected, directly the fill capsule gets final product.
Among the present invention, the alcoholic solution of magnesium stearate is that the 2-6g magnesium stearate is dissolved in 40-80ml ethanol because the dissolubility of magnesium stearate in alcohol be low, therefore, magnesium stearate added alcoholic solution after, can only form suspension under the room temperature.The concentration of alcoholic solution can be 75-95%, and those skilled in the art can select suitable concentration of alcohol and consumption according to prescription and practical operation condition.The present invention most preferably adds magnesium stearate in the alcoholic solution of 60ml85%.In addition, one skilled in the art will appreciate that heating can improve the dissolubility of magnesium stearate in ethanol, therefore, can heat the hot alcoholic solution spraying granule that magnesium stearate is adopted in the back, also can adopt the alcoholic acid suspension of magnesium stearate and room temperature ethanol.After the spraying, the magnesium stearate in the suspension also can evenly be adsorbed on particle surface, plays the effect of lubricant.
In addition, as a preferred embodiment of the present invention, in pelletization, adopt calcium dobesilate and the crosslinked Carboxymethyl cellulose sodium of 70%-90% to be prepared into granule with binding agent and recipe quantity 65%-95%, the alcoholic solution with magnesium stearate is sprayed to particle surface again.The calcium dobesilate of remaining 5%-35% and the crosslinked Carboxymethyl cellulose sodium powder of 10-30% are mixed with granule after the spraying, dryly then its intermediate is detected the fill capsule.In this technical scheme, the percentage by weight that utilizes this prescription calcium dobesilate is up to 95.3%, and the consumption of adjuvant is low, causes the supplementary material part of partly granulating directly can ignore with the content uniformity that powder fill capsule causes.In addition, magnesium stearate is sprayed to particle surface after, when mixing with remaining supplementary material powder, this granule itself also can play the effect of lubricant, improves the flowability of supplementary material powder, has further avoided content uniformity.And the mode one that adopts part to granulate is the back smaller volume of granulating, and helps capsular fill, in addition because powder than the easier moisture absorption of granule, adopts the particulate form fill of part also to help to improve stability of drug.
In two kinds of preparation methoies of the present invention, all relate to the particulate preparation of calcium dobesilate, concrete, the present invention adopts the multistep granulation, comprises the steps:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
The present invention adopts polyvinylpyrrolidone to prepare binding agent, and PVP has good physiology inertia, does not participate in the human body metabolism, has good biocompatibility again, is a kind of very ideal binding agent.In the early-stage Study, inventor's general knowledge multiple binding agent, the final discovery adopted polyvinylpyrrolidone to prepare binding agent and helped more to realize that multistep of the present invention granulates.Polyvinylpyrrolidone both can be water-soluble, can be dissolved in ethanol again, and those skilled in the art can be according to selecting any solvent, the alcoholic solution of preferably polyethylene ketopyrrolidine of the present invention in the actual production process.Wherein the consumption of polyvinylpyrrolidone is advisable with per 1000 capsules 2.5-5g, and most preferably in 1000 capsules, the consumption of polyvinylpyrrolidone is 3g.The ethanol of described ethanol preferred 95%.The visual concrete prescription of the consumption of concentration of ethanol, consumption and polyvinylpyrrolidone and slightly inching, this technology is known to those skilled in the art already.
(3) get 8/13 binding agent, mix, the system primary granule to the cross-linked carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35-65% and recipe quantity 30-70%;
(4) with adding 5/13 binding agent and the calcium dobesilate of recipe quantity 35-65%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-70% in the primary granule that makes, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying, fill.
As mentioned above, the present invention is by being divided into multistep with pelletization, first binding agent with 8/13 mixes most of calcium dobesilate and crosslinked Carboxymethyl cellulose sodium is made primary granule, mix with 5/13 binding agent mixing portion calcium dobesilate and crosslinked Carboxymethyl cellulose sodium again, further granulate, until no residual powder, granulate obtains intermediate grain, at last with the alcoholic solution of magnesium stearate to the processing of spraying of calcium dobesilate granule.
Granule by above-mentioned preparation method makes than the granule of available technology adopting with supplementary material powder and the direct mixing granulation preparation of binding agent, has good dissolution degree.After 5/13 binding agent adds in the step 4, the powder of the cross-linking sodium carboxymethyl cellulose of the calcium dobesilate of recipe quantity 35-65%, recipe quantity 30-70% forms the new primary granule except a part and binding agent, another part can stick to the primary granule surface, form the granule of multiple structure, so just obtained the different sizes calcium dobesilate granule different with structure.May be that the multiple structure of formation provides better stripping passage for the stripping of calcium dobesilate when adopting multistep to granulate.It also may be the stripping that unique space of forming between particles of different sizes more helps calcium dobesilate.The present invention controls particulate composition by the control adhesive consumption, reaches the purpose that improves dissolution.The present invention preferably carried out for two steps with 8/13,5/13 amount respectively with binding agent and granulates, but above-mentioned ratio is an optimal proportion, true if in the controlled step 3 in binding agent and the step 4 binder dosage be between the 1.2-2.5, can realize the raising of dissolution.
In addition, the concentration of alcohol of magnesium stearate also produces very big influence to whole preparation method, excessive concentration causes spray amount few, be difficult to the surface of even spraying at calcium hydrophenyl sulfonate capsule, be difficult to play lubricated and eliminate electrostatic effect, concentration is too low and cause spray amount excessive easily, causes the intermediate grain disintegrate, cause between the granule inter-adhesively, destroy the structure of multilayer particle.The inventor has done screening test according to prescription to the concentration of alcohol of magnesium stearate.The final discovery, when the concentration that is dissolved in the magnesium stearate of recipe quantity is that the 40-80ml alcoholic solution of 75-95% is, the time, can obtain satisfied spray effect, wherein, the consumption of preferred alcohol is 60ml; Concentration preferred 85%.
Drying in the step 5, the present invention adopts at 55-85 in fluid bed ℃, dry 0.5-1.5 hour; Preferably with 70 ℃, dry 0.5-1.5 hour.
The preparation method of two kinds of calcium hydrophenyl sulfonate capsules that the present invention is claimed includes the particulate preparation process of above-mentioned calcium dobesilate, distinctive points is: scheme one adopts all supplementary materials all is prepared into the calcium dobesilate granule, during fill directly with granule filling; Scheme two adopts the part supplementary material to make the calcium dobesilate granule, and the part supplementary material directly mixes with granule with powder, and the mode with granule+powder during fill pours into capsule shells.
In scheme one, the inventor further defines the consumption of supplementary material in the primary granule preparation.Be higher than with the consumption of strong this sodium sulfonate and crosslinked Carboxymethyl cellulose sodium in the elementary granulation that the consumption of the two is a basic principle in the intermediate grain process, specifically set and got 8/13 binding agent in the step 3, cross-linking sodium carboxymethyl cellulose to calcium dobesilate that wherein adds recipe quantity 45-60% and recipe quantity 40-70%, mix the system primary granule; In the step 4 primary granule that makes is put into fluid bed, add the cross-linking sodium carboxymethyl cellulose of 5/13 binding agent and recipe quantity 40-55%, the calcium dobesilate of 30-60% recipe quantity, further granulate, until no residual powder, granulate gets intermediate grain; Directly to the alcoholic solution of intermediate grain spraying magnesium stearate, mix drying, fill then.
As preferably, scheme one can specifically adopt following technical scheme:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds 55% recipe quantity and recipe quantity 60%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying, fill;
In the design of scheme two, the inventor adopts reserve part supplementary material powder directly to be used as medicine, and concrete supplementary material use amount is: get 8/13 binding agent, to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds the 35-50% recipe quantity and recipe quantity 40-50%, mix the system primary granule; The primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 30-45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-40%, further granulate, until no residual powder, granulate gets intermediate grain; To the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously carries out drying, fill with gained granule and the calcium dobesilate raw material powder of 5-35%, the cross-linked carboxymethyl cellulose raw material powder of 10-30% after the spraying.
As preferred embodiment, the preparation method of scheme two is:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 40% and recipe quantity 40%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 25% calcium dobesilate raw material powder, 25% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, fill.
More particularly, contain for per 1000 with prescription: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 35g, magnesium stearate 4g, polyvinylpyrrolidone 3g, prepare according to scheme two preferred manufacturing procedure, the calcium hydrophenyl sulfonate capsule quality of gained is the most stable, dissolution and content uniformity all are in optimum range, are the most preferred embodiments of the present invention.
In addition, in order to make more reasonable, the science of the claimed preparation method of the present invention, the inventor has done special test to the pretreatment and the capsular filling of crude drug, and is specific as follows:
The crude drug Study on pretreatment
Get this product crude drug, measure according to Chinese Pharmacopoeia version in 2005 two appendix IX E (granularity and particle size distribution method second method), the result can not account for 23.8% by the granule of 60 mesh sieves, handles after sieve after therefore working out in preparation is produced raw material pulverizing.
Get this product crude drug, cross 60,80,100 mesh sieves after the pulverizing respectively, measure angle of repose of powder respectively by fixing conical bottom method, the result is as follows:
Table 1 crude drug is measured angle of repose
Got by result of the test, the powder flowbility of crossing 100 mesh sieves is best, but does not satisfy the requirement of directly filling.
To discovering of this product crude drug, the crude drug powder surface is moistening, and certain viscosity is arranged, and influences particulate flowing.So planning crude drug dries processing,, improve powder flowbility to reduce or to eliminate this influence.
This product crude drug is pulverized the back cross 100 mesh sieves, carry out drying under 60 ± 5 ℃ of conditions, be 38.4 ° the angle of repose of measuring dried powder by fixing conical bottom method, and powder flowbility is better, can be directly used in the capsule filling.Work out this product crude drug pretreating process is in accordance with the law: pulverize the back and cross 100 mesh sieves, and dry under 60 ± 5 ℃ of conditions.
Drying process
Equipment: CT-C-II type heated-air circulation oven
Get the calcium dobesilate that makes by prescription of tentatively working out and preparation technology and the mixed powder of cross-linking sodium carboxymethyl cellulose, dry under 60 ℃ of conditions, respectively at sampling in the 0.5th, 1,2,3 hour, measure angle of repose, the result is as follows:
Table 2 is investigated drying time
Got by result of the test, after 1 hour, powder reaches minimum angle of repose in 60 ℃ of dryings, and powder has primary liquidity, satisfies the needs of subsequent technique.Work out drying process was in accordance with the law: in 60 ± 5 ℃ of dryings 1 hour.
Filling speed
Equipment: NJP1200D type fully-automatic capsule filling machine
The highest filling speed of capsule filling machine is 1200/minute, fill with 20 hertz (600/minute), 30 hertz (800/minute), 40 hertz (1000/minute), 50 hertz (1200 s'/minute) speed respectively, measure capsular content uniformity, the result is as follows:
Table 3 filling speed is investigated
According to the regulation of two appendix I of Chinese Pharmacopoeia version in 2005 E, the content uniformity limit of this product should be ± and 7.5%, be to guarantee product quality, the control content uniformity is in ± 5% scope in the preparation process.According to above-mentioned result of the test, take all factors into consideration production efficiency, working out the capsule filling speed is 800～1000/minute.
The calcium hydrophenyl sulfonate capsule related substance of the present invention's preparation is low, has effectively avoided content uniformity under the prerequisite that guarantees dissolution, and constant product quality is controlled.The prescription advantages of simple, preparation method is easy to operate, feasible process is stable.Its power consumption is few, can realize that suitability for industrialized production has considerable economic and social benefits, has very strong practicality.
The specific embodiment
Below be the specific embodiment of the present invention, described embodiment is in order to further describe the present invention, rather than restriction the present invention.
Embodiment 1
Capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ± 5 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 2.5-5g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 55% and recipe quantity 60%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 800/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 2
Capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 65 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 2.5-5g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 60% and recipe quantity 70%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 40%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 1000/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 3
Capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 63 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 2.5-5g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 50% and recipe quantity 55%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 50%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 45%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 900/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 4
Capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 2.5-5g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 65% and recipe quantity 70%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 800/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 5
Capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 58 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 25-50g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 45% and recipe quantity 65%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 55%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 900/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 6
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 5-10g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 58% and recipe quantity 60%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 42%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, is filled in the 0# Capsules, 800/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Embodiment 7
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 5-10g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 48% and recipe quantity 44%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 32%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 36%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 20% calcium dobesilate raw material powder, 20% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 800/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
Embodiment 8
Described particulate preparation method is as follows:
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 15g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 50% and recipe quantity 50%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 30%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 20% calcium dobesilate raw material powder, 20% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 1000/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
Embodiment 9
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 10g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 45% and recipe quantity 45%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 20% calcium dobesilate raw material powder, 20% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 950/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
Embodiment 10
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 3.5-5g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 50% and recipe quantity 50%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 5% calcium dobesilate raw material powder, 10% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 800/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
Embodiment 11
Described particulate preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 2.5-4g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35% and recipe quantity 40%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 30%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 35% calcium dobesilate raw material powder, 30% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 800/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
Embodiment 12
Described capsular preparation method is as follows:
(1) weighs each supplementary material, calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ℃ of dryings 1 hour;
(2) prepare binding agent with dissolve with ethanol 3g polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 40% and recipe quantity 40%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 25% calcium dobesilate raw material powder, 25% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected, according to being filled in the 0# Capsules, 900/minute of capsule filling speeds after the intermediate testing result calculating loading amount.
In order further to verify the science of prescription of the present invention and preparation method, the inventor has done following test:
Test the detection of 1 experimental example sample
The present invention adopts detection method commonly used in the prior art that the product relevant parameter of embodiment 1-12 is tested, and the results are shown in Table 4,5:
The assay of table 4 embodiment sample
The assay of table 5 embodiment sample
The above results shows, adopts the calcium dobesilate each side index of prescription of the present invention and preparation method preparation all qualified and significantly be better than prior art, steady quality.
Test example 2
This test example has been investigated and has been adopted the influence for the content uniformity of formulation products of prescription of the present invention and preparation method.The results are shown in Table 6.
Table 6 prescription of the present invention and preparation method are for the influence of the content uniformity of formulation products
Sequence number 1-5 is respectively 6 products of embodiment 1,3,7,9,12 in the last table;
Sequence number 6-10 is respectively disclosed embodiment 1-5 in the application number 200510110019.2;
Sequence number 11 is commercially available calcium hydrophenyl sulfonate capsule (calcium dobesilate) 0.5g*10s*2 plate/box (the sharp monarch's pharmacy in Xi'an);
Sequence number 12 is a disclosed calcium hydrophenyl sulfonate capsule in the prior art, and this capsular prescription is: calcium dobesilate-hydrate 521.5g (being equivalent to calcium dobesilate 500g), carboxymethyl starch sodium 45.0g, magnesium stearate 5.0g, make 1000.Employing is prepared from supplementary material powder direct filling method.
The above results shows, adopts prescription of the present invention and preparation method, and the content uniformity of gained calcium hydrophenyl sulfonate capsule is significantly less than prior art.
Test example 3
This test example has been investigated the stability of calcium hydrophenyl sulfonate capsule provided by the present invention, and result of the test sees Table 7,8.
Table 7, accelerated test
| 0 month | 1 month | 2 months | 3 months | 6 months | |
| 1 | 99.96 | 99.95 | 99.93 | 99.89 | 99.78 |
| 2 | 99.93 | 99.90 | 99.86 | 99.78 | 99.64 |
| 3 | 99.88 | 99.84 | 99.80 | 99.76 | 99.72 |
| 4 | 99.86 | 99.82 | 99.78 | 99.70 | 99.66 |
Table 8, long term test
| 0 month | 3 months | 6 months | 9 months | 12 months | 18 months | |
| 1 | 99.96 | 99.95 | 99.93 | 99.91 | 99.89 | 99.88 |
| 2 | 99.92 | 99.86 | 99.84 | 99.80 | 99.76 | 99.72 |
| 3 | 99.88 | 99.86 | 99.82 | 99.79 | 99.76 | 99.74 |
| 4 | 99.86 | 99.82 | 99.79 | 99.76 | 99.73 | 99.70 |
In this test, sequence number 1-4 product is got 50 for every group at random, detects stability data according to 2005 editions appendix XIX of Chinese Pharmacopoeia C method, gets each cell mean then, inserts table.
Wherein: 1 is the product according to embodiment 12 preparations;
Sequence number 2 is disclosed embodiment 1 in the application number 200510110019.2;
Sequence number 3 is commercially available calcium hydrophenyl sulfonate capsule (calcium dobesilate) 0.5g*10s*2 plate/box (the sharp monarch's pharmacy in Xi'an);
Sequence number 4 is a disclosed calcium hydrophenyl sulfonate capsule in the prior art, and this capsular prescription is: calcium dobesilate-hydrate 521.5g (being equivalent to calcium dobesilate 500g), carboxymethyl starch sodium 45.0g, magnesium stearate 5.0g, make 1000.Employing is prepared from supplementary material powder direct filling method.
The above results shows, adopts prescription of the present invention and preparation method, and the stability of gained calcium hydrophenyl sulfonate capsule has obtained the raising of significance.
The inventor has also done same test to other embodiment of the present invention, and the result has same trend, because length is limit, differs and one enumerates herein.
Claims (10)
1. calcium hydrophenyl sulfonate capsule, it is characterized in that: described capsule is prepared from by calcium dobesilate, cross-linking sodium carboxymethyl cellulose, magnesium stearate and polyvinylpyrrolidone, wherein per 1000 calcium hydrophenyl sulfonate capsules contain: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 20～50g, magnesium stearate 2～6g.
2. calcium hydrophenyl sulfonate capsule according to claim 1 is characterized in that: per 1000 of described calcium hydrophenyl sulfonate capsule contains: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 30～40g, magnesium stearate 3～5g.
3. calcium hydrophenyl sulfonate capsule according to claim 1 is characterized in that: described calcium hydrophenyl sulfonate capsule per 1000 contains: calcium dobesilate 500g, cross-linking sodium carboxymethyl cellulose 35g, magnesium stearate 4g.
4. the preparation method of calcium hydrophenyl sulfonate capsule according to claim 1 is characterized in that described preparation method comprises the particulate preparation of calcium dobesilate, and described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent, mix, the system primary granule to the cross-linked carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35-65% and recipe quantity 30-70%;
(4) with adding 5/13 binding agent and the calcium dobesilate of recipe quantity 35-65%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-70% in the primary granule that makes, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, fill.
5. preparation method according to claim 4 is characterized in that: the drying of described step 5 is carried out drying for the calcium dobesilate raw material powder of will granulate back gained granule and recipe quantity 0-35%, the cross-linked carboxymethyl cellulose raw material powder mixing of recipe quantity 0-40%.
6. preparation method according to claim 5 is characterized in that: described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 45-60% and recipe quantity 40-70%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 40-55%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-60%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, fill;
Preferred described particulate preparation method is:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 55% and recipe quantity 60%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) add the alcoholic solution of magnesium stearate to intermediate grain spraying, mix homogeneously, drying detects intermediate, fill;
7. preparation method according to claim 5 is characterized in that: described particulate preparation method is as follows:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 35-50% and recipe quantity 40-50%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 30-45%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 30-40%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously carries out drying with gained granule and the calcium dobesilate raw material powder of 5-35%, the cross-linked carboxymethyl cellulose raw material powder of 10-30% after the spraying, intermediate is detected fill;
Preferred described particulate preparation method is:
(1) weighs each supplementary material, and carry out pretreatment respectively;
(2) prepare binding agent with pure water or anhydrous alcohol solution polyvinylpyrrolidone;
(3) get 8/13 binding agent,, mix, the system primary granule to the cross-linking sodium carboxymethyl cellulose of calcium dobesilate that wherein adds recipe quantity 40% and recipe quantity 40%;
(4) primary granule that makes is put into fluid bed, add the calcium dobesilate of 5/13 binding agent and recipe quantity 35%, the cross-linking sodium carboxymethyl cellulose of recipe quantity 35%, further granulate, until no residual powder, granulate gets intermediate grain;
(5) to the alcoholic solution of intermediate grain spraying adding magnesium stearate, mix homogeneously is granulated; Gained granule and 25% calcium dobesilate raw material powder, 25% cross-linked carboxymethyl cellulose raw material powder after the spraying are carried out drying, intermediate is detected fill.
8. preparation method according to claim 4 is characterized in that: pretreatment is in the described step 1: calcium dobesilate and Carboxymethyl cellulose sodium are crossed 100 mesh sieves respectively, in 60 ± 5 ℃ of dryings 1 hour.
9. according to each described preparation method of claim 5-7, it is characterized in that: the alcoholic solution in the described step 5 is 40-80ml, preferred 60ml; Concentration of alcohol is 75-95%, preferred 85%.
10. according to each described preparation method of claim 5-7, it is characterized in that: the drying in the described step 5 is in fluid bed 55-85 ℃, dry 0.5-1.5 hour; Preferably with 70 ℃, dry 0.5-1.5 hour, be filled in the 0# Capsules, 800～1000/minute of capsule filling speeds after calculating loading amount according to the intermediate testing result.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110030889 CN102091055B (en) | 2011-01-28 | 2011-01-28 | Calcium dobesilate capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110030889 CN102091055B (en) | 2011-01-28 | 2011-01-28 | Calcium dobesilate capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102091055A true CN102091055A (en) | 2011-06-15 |
| CN102091055B CN102091055B (en) | 2013-09-18 |
Family
ID=44124436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110030889 Expired - Fee Related CN102091055B (en) | 2011-01-28 | 2011-01-28 | Calcium dobesilate capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102091055B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102416006A (en) * | 2011-12-05 | 2012-04-18 | 上海朝晖药业有限公司 | Calcium dobesilate capsules and preparation method thereof |
| CN103230383A (en) * | 2013-03-31 | 2013-08-07 | 北京万全阳光医学技术有限公司 | Calcium dobesilate capsule composition and preparation method thereof |
| CN104622842A (en) * | 2014-12-23 | 2015-05-20 | 北京京丰制药集团有限公司 | Calcium dobesilate capsule and preparation method thereof |
| CN110123776A (en) * | 2019-05-17 | 2019-08-16 | 贵州天安药业股份有限公司 | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771927A (en) * | 2005-11-03 | 2006-05-17 | 上海复星朝晖药业有限公司 | Calcium hydrophenyl sulfonate capsule and its prepn process |
| WO2006069806A1 (en) * | 2004-12-30 | 2006-07-06 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical composition comprinsing a 2,5-dihydroxybenzenesulfonic compounds, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| CN1939291A (en) * | 2006-09-29 | 2007-04-04 | 何岩 | Hydroxyphenyl sulfonated calcium slow-releasing preparation |
| CN101822648A (en) * | 2009-03-04 | 2010-09-08 | 姚春霞 | Preparation method and application of nano dobesilate calcium capsule or tablet |
-
2011
- 2011-01-28 CN CN 201110030889 patent/CN102091055B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069806A1 (en) * | 2004-12-30 | 2006-07-06 | Laboratorios Del Dr. Esteve, S.A. | Pharmaceutical composition comprinsing a 2,5-dihydroxybenzenesulfonic compounds, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| CN1771927A (en) * | 2005-11-03 | 2006-05-17 | 上海复星朝晖药业有限公司 | Calcium hydrophenyl sulfonate capsule and its prepn process |
| CN1939291A (en) * | 2006-09-29 | 2007-04-04 | 何岩 | Hydroxyphenyl sulfonated calcium slow-releasing preparation |
| CN101822648A (en) * | 2009-03-04 | 2010-09-08 | 姚春霞 | Preparation method and application of nano dobesilate calcium capsule or tablet |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102416006A (en) * | 2011-12-05 | 2012-04-18 | 上海朝晖药业有限公司 | Calcium dobesilate capsules and preparation method thereof |
| CN103230383A (en) * | 2013-03-31 | 2013-08-07 | 北京万全阳光医学技术有限公司 | Calcium dobesilate capsule composition and preparation method thereof |
| CN104622842A (en) * | 2014-12-23 | 2015-05-20 | 北京京丰制药集团有限公司 | Calcium dobesilate capsule and preparation method thereof |
| CN104622842B (en) * | 2014-12-23 | 2017-06-06 | 北京京丰制药集团有限公司 | A kind of calcium hydrophenyl sulfonate capsule and preparation method thereof |
| CN110123776A (en) * | 2019-05-17 | 2019-08-16 | 贵州天安药业股份有限公司 | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102091055B (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091055B (en) | Calcium dobesilate capsule and preparation method thereof | |
| CN103070864A (en) | Repaglinide and metformin hydrochloride medicinal composition and its preparation method | |
| CN101851247B (en) | Composition containing clopidogrel bisulfate crystal particles | |
| CN111973565A (en) | Vonoprazan fumarate-containing tablet and dissolution rate determination method thereof | |
| CN101810628B (en) | Melbine glipizide tablet and preparation method thereof | |
| CN104814923B (en) | A kind of tamsulosin hydrochloride sustained release preparation and preparation method thereof and its application | |
| CN101342177B (en) | Lornoxicam double-layer sustained release tablets | |
| CN102379855A (en) | Glimepiride dispersible tablet and preparation method thereof | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| EP1541161A1 (en) | Tablet composition containing chinese orthodox medicine extract and process for producing the same | |
| CN103083314A (en) | Compound ibuprofen having gastrointestinal protective effect | |
| CN103705515A (en) | Method for preparing pharmaceutical composition containing repaglinide and metformin hydrochloride | |
| CN100425228C (en) | Dispersion tablets and its prepn. method | |
| CN110051639B (en) | Rapidly disintegrating nicergoline tablet and preparation method thereof | |
| CN104434873A (en) | Calcium dobesilate capsule | |
| CN101716162B (en) | Aminophylline slow-release capsules and preparation method thereof | |
| CN101711753A (en) | Preparation method of lansoprazole solid preparation | |
| KR100735904B1 (en) | Tablet composition containing extract of natural herbal plants and its manufacturing process | |
| CN103432082A (en) | Glucosamine composition and preparation method thereof | |
| CN1303979C (en) | Preparation of snake gallbladder and tangerine peel dispersed tablets | |
| WO2023173460A1 (en) | Pharmaceutical composition of sglt-2 inhibitor | |
| CN103520156B (en) | One is not containing talcous α keto acid compound and preparation technology thereof | |
| CN104840442B (en) | A kind of sustained-release tablet containing quetiapine fumarate and preparation method thereof | |
| CN104414988A (en) | Dasatinib tablet and preparation process thereof | |
| CN103110601A (en) | Gliclazide gastric floating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee after: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. Address before: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee before: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20220128 |